Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus MYMETHAZINE FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus MYMETHAZINE FORTIS.
ACTAHIST vs MYMETHAZINE FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
1.34 mg (one capsule) orally twice daily.
50 mg orally every 6 hours as needed for nausea and vomiting.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination